comparemela.com

Latest Breaking News On - Guillermo garcia manero - Page 11 : comparemela.com

Discoveries & Impact (January 2023)

Discoveries & Impact highlights select scientific discoveries across the Department of Internal Medicine.

United-states
South-korea
Michigan
Han
American
Michael-chiorazzi
George-zhang
Rachelj-perry
Valeria-santini
Mikkaela-sekeres
Tarun-tyagi
Uwe-platzbecker

Taiho Oncology and Astex Pharmaceuticals Present Overall Survival Data for Oral Decitabine and Cedazuridine (INQOVI®, ASTX727) in Patients With MDS and CMML Harboring TP53 Mutations at 64th ASH An...

Patients in Phase 3 ASCERTAIN study with biallelic TP53 mutations achieved median overall survival (mOS) of 13 months; mOS in the overall study po.

Oakville
Ontario
Canada
United-states
New-jersey
United-kingdom
France
Switzerland
Canadian
French
American
British

Curis Announces Date for the 1st Symposium on IRAK4 in Cancer

/PRNewswire/ Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today.

Minnesota
United-states
Netherlands
Cincinnati
Ohio
Texas
Robert-martell
Amit-verma
Grzegorz-nowakowski
Edwardp-evans
James-dentzer
Marc-raaijmakers

What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting

Emphasis on novel biological approaches in treating patients with hematologic malignancies

New-york
United-states
Phoenix
Arizona
Memorial-sloan-kettering-cancer-center
Houston
Texas
Massachusetts
Saadz-usmani
Mike-bassett
Johnc-byrd
Thomasg-martin

Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes

Overall response rates were 67% with decitabine, 48% with azacitidine

Houston
Texas
United-states
Massachusetts
Mike-bassett
Guillermo-garcia-manero
University-of-texas-md-anderson-cancer-center
Eastern-cooperative-oncology-group
Cancer-center

vimarsana © 2020. All Rights Reserved.